Who founded Go Therapeutics?

Go Therapeutics was founded by Hans Wandall.

How much funding has Go Therapeutics raised?

Go Therapeutics has disclosed $5M raised across 1 round.

Where is Go Therapeutics headquartered?

Go Therapeutics is headquartered in Cambridge, US.

Go Therapeutics

Cambridge, US · Delaware corporation

GO Therapeutics mines the cancer glycoproteome for cancer-specific epitopes and develops high-affinity antibodies used to create ADCs, CAR T cell therapies, and companion diagnostics targeting solid tumors. The company runs in-house and partnered drug discovery programs based on its glycopeptide biology platform.

Biotech Healthtech

Founders & leadership

Hans WandallScientific Co-Founder & Chief Scientific Officer

Constantine TheodoropulosCo-Founder & Chief Executive Officer

Thayer WhiteNamed on SEC filing

Gregory L. ChaseNamed on SEC filing

Aaron C. GroenDirector of Biology

Reported raises · per SEC filings

Form D private placements

$5M disclosed across 1 round · 2017

▶$5MraisedAug 2017 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Constantine TheodoropulosExecutive Officer, Director
Thayer WhiteDirector
Gregory L. ChaseDirector

Offering amount: $5M
Amount sold: $5M
First sale: Aug 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap

Apogee Therapeutics8 shared keywordsApogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care. Its pipeline addresses dermatological, respiratory, and gastroenterological conditions.

G1 Therapeutics6 shared keywordsG1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

Applied Therapeutics4 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.

Kite Pharma4 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.

Protego4 shared keywordsProtego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones. Its work targets patients affected by protein misfolding disorders.

Fate Therapeutics4 shared keywordsFate Therapeutics develops clinical-stage cell therapy drug candidates for autoimmune diseases and cancer, using an induced pluripotent stem cell (iPSC) platform to create off-the-shelf, multiplexed-engineered cell products. Its therapies aim to overcome manufacturing and commercialization limitations of conventional cell therapies.

Companies competing with Go Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Go Therapeutics do?: GO Therapeutics mines the cancer glycoproteome for cancer-specific epitopes and develops high-affinity antibodies used to create ADCs, CAR T cell therapies, and companion diagnostics targeting solid tumors. The company runs in-house and partnered drug discovery programs based on its glycopeptide biology platform.
Who founded Go Therapeutics?: Go Therapeutics was founded by Hans Wandall.
How much funding has Go Therapeutics raised?: Go Therapeutics has disclosed $5M raised across 1 round.
Where is Go Therapeutics headquartered?: Go Therapeutics is headquartered in Cambridge, US.